세계의 글루카곤 시장 규모는 2023년에 6억 800만 달러로 평가되며, 예측 기간(2025-2032년)의 CAGR은 6.0%로, 2024년 6억 4,448만 달러에서 2032년에는 10억 2,720만 달러로 성장할 것으로 예측됩니다.
세계 글루카곤 시장은 당뇨병 유병률 증가, 응급의료 치료의 채택 증가, 중증 저혈당 관리에 대한 인식이 높아짐에 따라 강력한 성장세를 보이고 있습니다. 의료 시스템이 신뢰할 수 있는 치료 옵션을 우선시함에 따라 효과적인 저혈당 치료에 대한 수요가 급증하고 있습니다. 응급용 주사제 및 비강용 제제의 발전은 환자의 예후를 개선하고 시장 침투력을 높이고 있습니다. 저혈당 에피소드에 대한 응급 대응에 대해 의료 전문가와 환자를 교육하는 노력은 그 수요를 더욱 확대시키고 있습니다. 또한 약물전달 시스템의 기술 혁신이 진행되고 있고, 정부의 우호적인 의료 정책도 시장 확대에 힘을 보태고 있습니다. 그러나 고가의 치료비, 저소득 지역에서의 충분한 인지도, 규제 장벽, 콜드체인 물류에 대한 의존도 등의 문제는 시장 전략과 지역적 수용에 계속 영향을 미치고 있습니다.
Global Glucagon Market size was valued at USD 608.0 million in 2023 and is poised to grow from USD 644.48 million in 2024 to USD 1027.2 million by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).
The global glucagon market is witnessing robust growth driven by the escalating prevalence of diabetes, increased adoption of emergency medical treatments, and heightened awareness surrounding severe hypoglycemia management. Demand for effective hypoglycemia interventions is surging as healthcare systems prioritize reliable treatment options. Advancements in emergency injectable solutions and nasal glucagon formulations are improving patient outcomes and enhancing market penetration. Efforts to educate healthcare professionals and patients on the urgency of addressing hypoglycemic episodes are further amplifying demand. Additionally, ongoing innovations in drug delivery systems and favorable government healthcare policies are fostering market expansion. However, challenges such as high treatment costs, insufficient awareness in lower-income regions, regulatory hurdles, and reliance on cold-chain logistics continue to impact market strategies and regional uptake.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glucagon market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Glucagon Market Segments Analysis
Global Glucagon Market is segmented by Indication, Route of Administration, Formulation, End-User and region. Based on Indication, the market is segmented into Hypoglycemia, Diabetic Ketoacidosis and Metabolic Disease Trials. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Intramuscular. Based on Formulation, the market is segmented into Injectable Kits, Liquid Stable Autoinjectors, Nasal Powder and Liquid Stable Vials. Based on End-User, the market is segmented into Hospitals, Clinic, Drug Stores, Online Pharmacies and Home Care Setting. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Glucagon Market
The rising prevalence of diabetes, particularly type 1 diabetes, worldwide is a significant factor propelling the growth of the glucagon market. Individuals living with insulin-dependent diabetes face the constant risk of severe hypoglycemia, which requires prompt intervention. This urgent healthcare necessity has led to a heightened demand for glucagon treatment options in various settings, including hospitals, clinics, and homecare environments. As the awareness of diabetes management and emergency response continues to expand, the need for effective glucagon solutions becomes more pronounced, further fueling the market's expansion and innovation in treatment methods.
Restraints in the Global Glucagon Market
The advanced glucagon delivery systems, including prefilled autoinjectors and nasal powders, present significant financial challenges due to their high development and production costs. This elevated pricing may hinder their acceptance, particularly in low- and middle-income countries, where affordability is a critical concern. Additionally, these expenses place a burden on healthcare systems and insurance providers, complicating the wider distribution and accessibility of innovative treatment options. As a result, the potential benefits of these modern glucagon formulations may not be realized on a broad scale, limiting the overall impact on patient care and health outcomes.
Market Trends of the Global Glucagon Market
The Global Glucagon market is experiencing notable growth driven by advancements in drug delivery technologies, such as liquid-stable formulations, nasal sprays, and autoinjectors. These innovations enhance the convenience and efficacy of glucagon administration, eliminating the need for reconstitution and improving shelf stability. This ease of use is particularly beneficial during emergencies, as it allows for prompt intervention in cases of severe hypoglycemia. As healthcare providers and patients increasingly demand more user-friendly solutions, the market is poised for expansion, reflecting a broader trend towards patient-centric approaches in diabetes management and emergency care.